JAZZ - Jazz Pharmaceuticals EPS beats by $0.60 beats on revenue August, 04 2020 04:09 PM Jazz Pharmaceuticals plc Jazz Pharmaceuticals (NASDAQ:JAZZ): Q2 Non-GAAP EPS of $3.71 beats by $0.60; GAAP EPS of $2.06 beats by $0.21.Revenue of $562.4M (+5.3% Y/Y) beats by $59.21M.R&D $78.9M vs. $63.7M consensus.Press ReleaseMore news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news,